Updated on 2025/02/11

写真a

 
KIMURA Michael Atsushi
 
Organization
Brain Research Institute Center for Integrated Human Brain Science Specially Appointed Assistant Professor
Title
Specially Appointed Assistant Professor
External link

Degree

  • 博士(医学) ( 2021.9   昭和大学 )

  • 学士(医学) ( 2015.3   新潟大学 )

Research Interests

  • Alzheimer's Disease

  • Positron Emission Tomography

  • β Amyloid

  • oligomers

  • magnetic resonance imaging

  • bioimaging

  • Python

  • polyphenols

  • vitamin B12

  • myricetin

  • MATLAB

  • FreeSurfer

  • α-Synuclein

  • surface-based morphometry

Research Areas

  • Life Science / Pharmaceutical hygiene and biochemistry

  • Life Science / Neurology

  • Life Science / Radiological sciences

Research History (researchmap)

  • Niigata University   Brain Research Institute Center for Integrated Human Brain Science Department of Functional Neurology and Neurosurgery   Assistant Professor

    2024.5

      More details

  • Showa University   Clinical Research Institute for Clinical Pharmacology and Therapeutics

    2022.10

      More details

  • Niigata University   Brain Research Institute Center for Integrated Human Brain Science Department of Functional Neurology and Neurosurgery   visiting lecturer

    2022.10 - 2024.4

      More details

  • Showa University   Pharmacology Research Center   post-graduate student

    2018.10 - 2021.9

      More details

  • Showa University   Department of Medicine, Division of Neurology   Assistant Professor

    2017.4 - 2021.9

      More details

  • Tokyo Teishin Hospital

    2015.4

      More details

▶ display all

Research History

  • Niigata University   Center for Integrated Human Brain Science, Brain Research Institute   Specially Appointed Assistant Professor

    2024.5

Education

  • Showa University Graduate School   Department of Pharmacology

    2017.10 - 2021.9

      More details

  • Niigata University   Department of medicine   医学科

    2009.4 - 2015.3

      More details

Professional Memberships

  • Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)

      More details

  • The japanese headache society

      More details

  • JAPANESE SOCIETY OF NEUROLOGY

      More details

  • THE JAPANESE SOCIETY OF INTERNAL MEDICINE

      More details

  • JAPAN SOCIETY FOR DEMENTIA RESEARCH

      More details

 

Papers

  • A case of cerebral amyloid angiopathy with ipsilateral tau and contralateral amyloid PET uptake related to cadaveric dura mater implanted in childhood Reviewed

    Yuki Hatakeyama, Atsushi Michael Kimura, Shintaro Tsuboguchi, Mikhail Ratanov, Kosei Nakamura, Masahiro Hatakeyama, Yukimi Nakamura, Masaki Watanabe, Yoshihiro Murakami, Yuko Saito, Shigeo Murayama, Kensaku Kasuga, Takeshi Ikeuchi, Hironaka Igarashi, Osamu Onodera, Hitoshi Shimada

    European Journal of Nuclear Medicine and Molecular Imaging   2024.12

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s00259-024-07030-z

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s00259-024-07030-z/fulltext.html

  • Investigation of the relationship between thiamine and cognitive function/cerebral blood flow in Alzheimer's disease

    木村 篤史, 森 友紀子, 黒田 岳志, 金野 竜太, 矢野 怜, 畠山 公大, 島田 斉, 村上 秀友, 小野 賢二郎

    Dementia Japan   38 ( 4 )   682 - 682   2024.10

     More details

    Language:Japanese   Publisher:(一社)日本認知症学会  

    researchmap

  • Corticobasal syndrome mimicking Foix-Chavany-Marie syndrome with suggested 4-repeat tauopathy by tau PET. Reviewed International journal

    Kosei Nakamura, Yasuko Kuroha, Masahiro Hatakeyama, Atsushi Michael Kimura, Yukimi Nakamura, Yoshihiro Murakami, Masaki Watanabe, Hironaka Igarashi, Tetsuya Takahashi, Hitoshi Shimada

    BMC geriatrics   23 ( 1 )   838 - 838   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Corticobasal syndrome (CBS) is a neurodegenerative disease diagnosed based on clinical manifestations such as asymmetrical parkinsonism, limb apraxia, and speech and language impairment. The background pathology of CBS is commonly a variety of proteinopathies, but association with cerebrovascular disease has also been reported. Foix-Chavany-Marie syndrome (FCMS) is a rare neurological disorder characterized by facio-pharyngo-glossal diplegia with automatic-voluntary movement dissociation presenting with bilateral paresis of the facial, lingual, pharyngeal and masticatory muscles. FCMS is commonly attributable to stroke. Transactive response DNA binding protein of 43 kD (TDP-43) proteinopathy is also known as the pathological background of FCMS, while the pathological background of the majority of CBS cases consists of diverse tauopathies instead of TDP-43 proteinopathy. In this report, we describe a case mimicking FCMS that was finally diagnosed as CBS with suggested 4-repeat tauopathy. CASE PRESENTATION: A 68-year-old female started experiencing difficulty speaking followed by difficulty writing, and especially texting, several years before her visit. Her impairment had been gradually worsening, and she came to our hospital. On neurological examination, she demonstrated the facial apraxia, frontal lobe dysfunction, and upper motor neuron signs. She presented some characteristics suggestive of FCMS. Her symptoms exhibited rapid progression and myoclonus, parkinsonism, and left-side dominant cortical sensory deficit occurred, resulting in the fulfillment of diagnostic criteria for CBS after 9 months. Tau PET imaging displayed notable ligand uptake in the brainstem, subthalamic nuclei, basal ganglia, and bilateral subcortical frontal lobe, suggesting that her pathological background was 4-repeat tauopathy. As a result of her progressive dysphagia, she became unable to eat and passed away after 12 months. CONCLUSION: We hereby present an atypical case of CBS showing clinical features mimicking FCMS at first presentation. TDP-43 proteinopathy was suspected based on the clinical symptoms in the early stages of the disease; however, the clinical course and imaging findings including tau PET suggested that her pathological background was 4-repeat tauopathy.

    DOI: 10.1186/s12877-023-04564-z

    PubMed

    researchmap

  • Extracellular high molecular weight α-synuclein oligomers induce cell death by disrupting the plasma membrane. Reviewed International journal

    Naohito Ito, Mayumi Tsuji, Naoki Adachi, Shiro Nakamura, Avijite Kumer Sarkar, Kensuke Ikenaka, César Aguirre, Atsushi Michael Kimura, Yuji Kiuchi, Hideki Mochizuki, David B Teplow, Kenjiro Ono

    NPJ Parkinson's disease   9 ( 1 )   139 - 139   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    α-Synuclein (αS), the causative protein of Parkinson's disease and other α-synucleinopathies, aggregates from a low molecular weight form (LMW-αS) to a high molecular weight αS oligomer (HMW-αSo). Aggregated αS accumulates intracellularly, induces intrinsic apoptosis, is released extracellularly, and appears to propagate disease through prion-like spreading. Whether extracellular αS aggregates are cytotoxic, damage cell wall, or induce cell death is unclear. We investigated cytotoxicity and cell death caused by HMW-αSo or LMW-αS. Extracellular HMW-αSo was more cytotoxic than LMW-αS and was a crucial factor for inducing plasma membrane damage and cell death. HMW-αSo induced reactive oxygen species production and phospholipid peroxidation in the membrane, thereby impairing calcium homeostasis and disrupting plasma membrane integrity. HMW-αSo also induced extrinsic apoptosis and cell death by activating acidic sphingomyelinase. Thus, as extracellular HMW-αSo causes neuronal injury and death via cellular transmission and direct plasma membrane damage, we propose an additional disease progression pathway for α-synucleinopathies.

    DOI: 10.1038/s41531-023-00583-0

    PubMed

    researchmap

  • The Curcumin Derivative GT863 Protects Cell Membranes in Cytotoxicity by Aβ Oligomers Reviewed

    Yutaro Momma, Mayumi Tsuji, Tatsunori Oguchi, Hideaki Ohashi, Tetsuhito Nohara, Naohito Ito, Ken Yamamoto, Miki Nagata, Atsushi Michael Kimura, Shiro Nakamura, Yuji Kiuchi, Kenjiro Ono

    International Journal of Molecular Sciences   24 ( 4 )   3089 - 3089   2023.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    In Alzheimer’s disease (AD), accumulation of amyloid β-protein (Aβ) is one of the major mechanisms causing neuronal cell damage. Disruption of cell membranes by Aβ has been hypothesized to be the important event associated with neurotoxicity in AD. Curcumin has been shown to reduce Aβ-induced toxicity; however, due to its low bioavailability, clinical trials showed no remarkable effect on cognitive function. As a result, GT863, a derivative of curcumin with higher bioavailability, was synthesized. The purpose of this study is to clarify the mechanism of the protective action of GT863 against the neurotoxicity of highly toxic Aβ oligomers (Aβo), which include high-molecular-weight (HMW) Aβo, mainly composed of protofibrils in human neuroblastoma SH-SY5Y cells, focusing on the cell membrane. The effect of GT863 (1 μM) on Aβo-induced membrane damage was assessed by phospholipid peroxidation of the membrane, membrane fluidity, membrane phase state, membrane potential, membrane resistance, and changes in intracellular Ca2+ ([Ca2+]i). GT863 inhibited the Aβo-induced increase in plasma-membrane phospholipid peroxidation, decreased membrane fluidity and resistance, and decreased excessive [Ca2+]i influx, showing cytoprotective effects. The effects of GT863 on cell membranes may contribute in part to its neuroprotective effects against Aβo-induced toxicity. GT863 may be developed as a prophylactic agent for AD by targeting inhibition of membrane disruption caused by Aβo exposure.

    DOI: 10.3390/ijms24043089

    researchmap

  • Combined Treatment with Curcumin and Ferulic Acid Suppressed the Aβ-Induced Neurotoxicity More than Curcumin and Ferulic Acid Alone Reviewed

    Hideaki Ohashi, Mayumi Tsuji, Tatsunori Oguchi, Yutaro Momma, Tetsuhito Nohara, Naohito Ito, Ken Yamamoto, Miki Nagata, Atsushi Michael Kimura, Yuji Kiuchi, Kenjiro Ono

    International Journal of Molecular Sciences   23 ( 17 )   9685 - 9685   2022.8

     More details

    Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    Alzheimer’s disease (AD) is a neurodegenerative disease that leads to progressive cognitive decline. Several effective natural components have been identified for the treatment of AD. However, it is difficult to obtain conclusive evidence on the safety and effectiveness of natural components, because a variety of factors are associated with the progression of AD pathology. We hypothesized that a therapeutic effect could be achieved by combining multiple ingredients with different efficacies. The purpose of this study was thus to evaluate a combination treatment of curcumin (Cur) and ferulic acid (FA) for amyloid-β (Aβ)-induced neuronal cytotoxicity. The effect of Cur or FA on Aβ aggregation using thioflavin T assay was confirmed to be inhibited in a concentration-dependent manner by Cur single or Cur + FA combination treatment. The effects of Cur + FA on the cytotoxicity of human neuroblastoma (SH-SY5Y) cells induced by Aβ exposure were an increase in cell viability, a decrease in ROS and mitochondrial ROS, and repair of membrane damage. Combination treatment showed an overall higher protective effect than treatment with Cur or FA alone. These results suggest that the combined action mechanisms of Cur and FA may be effective in preventing and suppressing the progression of AD.

    DOI: 10.3390/ijms23179685

    researchmap

  • 早期の免疫治療により良好な転帰を辿ったNew-onset refractory status epilepticusの27歳女性例

    松岡 馨, 小澤 準之輔, 浅野 未希, 木村 篤史, イズデプスキ 彬子, 久保田 怜美, 飯塚 奈都子, 渡辺 慶子, 黒田 岳志, 稗田 宗太郎, 小野 賢二郎

    臨床神経学   62 ( 8 )   647 - 647   2022.8

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

    researchmap

  • 早期の免疫治療により良好な転帰を辿ったNew-onset refractory status epilepticusの27歳女性例

    松岡 馨, 小澤 準之輔, 浅野 未希, 木村 篤史, イズデプスキ 彬子, 久保田 怜美, 飯塚 奈都子, 渡辺 慶子, 黒田 岳志, 稗田 宗太郎, 小野 賢二郎

    臨床神経学   62 ( 8 )   647 - 647   2022.8

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

    researchmap

  • 血清BDNFのアルツハイマー病のバイオマーカーの可能性

    森 友紀子, 辻 まゆみ, 小口 達敬, 春日 健作, 木村 篤史, 二村 明徳, 杉本 あずさ, 笠井 英世, 黒田 岳志, 矢野 怜, 稗田 宗太郎, 木内 祐二, 池内 健, 小野 賢二郎

    Dementia Japan   35 ( 4 )   618 - 618   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本認知症学会  

    researchmap

  • Myricetin prevents high molecular weight Aβ1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria Reviewed International journal

    Atsushi Michael Kimura, Mayumi Tsuji, Taro Yasumoto, Yukiko Mori, Tatsunori Oguchi, Yuya Tsuji, Masakazu Umino, Asami Umino, Toru Nishikawa, Shiro Nakamura, Tomio Inoue, Yuji Kiuchi, Masahito Yamada, David B. Teplow, Kenjiro Ono

    Free Radical Biology and Medicine   171   232 - 244   2021.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    Excessive accumulation of amyloid β-protein (Aβ) is one of the primary mechanisms that leads to neuronal death with phosphorylated tau in the pathogenesis of Alzheimer's disease (AD). Protofibrils, one of the high-molecular-weight Aβ oligomers (HMW-Aβo), are implicated to be important targets of disease modifying therapy of AD. We previously reported that phenolic compounds such as myricetin inhibit Aβ1-40, Aβ1-42, and α-synuclein aggregations, including their oligomerizations, which may exert protective effects against AD and Parkinson's disease. The purpose of this study was to clarify the detailed mechanism of the protective effect of myricetin against the neurotoxicity of HMW-Aβo in SH-SY5Y cells. To assess the effect of myricetin on HMW-Aβo-induced oxidative stress, we systematically examined the level of membrane oxidative damage by measuring cell membrane lipid peroxidation, membrane fluidity, and cell membrane potential, and the mitochondrial oxidative damage was evaluated by mitochondrial permeability transition (MPT), mitochondrial reactive oxygen species (ROS), and manganese-superoxide dismutase (Mn-SOD), and adenosine triphosphate (ATP) assay in SH-SY5Y cells. Myricetin has been found to increased cell viability by suppression of HMW-Aβo-induced membrane disruption in SH-SY5Y cells, as shown in reducing membrane phospholipid peroxidation and increasing membrane fluidity and membrane resistance. Myricetin has also been found to suppress HMW-Aβo-induced mitochondria dysfunction, as demonstrated in decreasing MPT, Mn-SOD, and ATP generation, raising mitochondrial membrane potential, and increasing mitochondrial-ROS generation. These results suggest that myricetin preventing HMW-Aβo-induced neurotoxicity through multiple antioxidant functions may be developed as a disease-modifying agent against AD.

    DOI: 10.1016/j.freeradbiomed.2021.05.019

    PubMed

    researchmap

  • Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy Reviewed International journal

    Yukiko Mori, Mayumi Tsuji, Tatsunori Oguchi, Kensaku Kasuga, Atsushi Kimura, Akinori Futamura, Azusa Sugimoto, Hideyo Kasai, Takeshi Kuroda, Satoshi Yano, Sotaro Hieda, Yuji Kiuchi, Takeshi Ikeuchi, Kenjiro Ono

    Frontiers in Neurology   12   653267 - 653267   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Frontiers Media SA  

    There is an urgent need to establish blood biomarkers for Alzheimer's disease (AD). Although it has been speculated that brain-derived neurotrophic factor (BDNF) is associated with AD, whether it can be used as a blood biomarker has yet to be determined. We used serum, cerebrospinal fluid (CSF), and medial temporal lobe atrophy from patients with AD to evaluate the association of BDNF with AD and assess its severity. For the blood analysis, 66 participants [21 normal controls (NCs) with normal cognitive function, 22 patients with mild cognitive impairment (MCI) due to AD, and 23 patients with AD] were included. For the CSF analysis, 30 participants were included. Magnetic resonance imaging, including a voxel-based specific regional analysis system for AD, and a Mini Mental State Examination were performed. Serum levels of BDNF and CSF levels of amyloid-β<sub>42</sub>, total tau, and phosphorylated tau were measured using ELISA. Serum BDNF levels were significantly lower in the MCI due to AD group than in the NC group (<italic>p</italic> = 0.037). Although there was no significant difference in the AD group, there was a downward trend compared to the NC group. Serum BDNF levels were positively correlated with CSF Aβ<sub>42</sub> levels (<italic>r</italic> = 0.49, <italic>p</italic> = 0.005). There was a significant correlation between serum BDNF levels and medial temporal lobe atrophy. Decreased serum BDNF can potentially be used as a biomarker for early AD detection. Early detection of AD with a less invasive blood test is very beneficial, as it allows for intervention before dementia progresses.

    DOI: 10.3389/fneur.2021.653267

    PubMed

    researchmap

  • High molecular weight amyloid β1-42 oligomers induce neurotoxicity via plasma membrane damage. Reviewed International journal

    Taro Yasumoto, Yusaku Takamura, Mayumi Tsuji, Takahiro Watanabe-Nakayama, Keiko Imamura, Haruhisa Inoue, Shiro Nakamura, Tomio Inoue, Atsushi Kimura, Satoshi Yano, Hisao Nishijo, Yuji Kiuchi, David B Teplow, Kenjiro Ono

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology   33 ( 8 )   9220 - 9234   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Amyloid β-protein (Aβ) molecules tend to aggregate and subsequently form low MW (LMW) oligomers, high MW (HMW) aggregates such as protofibrils, and ultimately fibrils. These Aβ species can generally form amyloid plaques implicated in the neurodegeneration of Alzheimer disease (AD), but therapies designed to reduce plaque load have not demonstrated clinical efficacy. Recent evidence implicates amyloid oligomers in AD neuropathology, but the precise mechanisms are uncertain. We examined the mechanisms of neuronal dysfunction from HMW-Aβ1-42 exposure by measuring membrane integrity, reactive oxygen species (ROS) generation, membrane lipid peroxidation, membrane fluidity, intracellular calcium regulation, passive membrane electrophysiological properties, and long-term potentiation (LTP). HMW-Aβ1-42 disturbed membrane integrity by inducing ROS generation and lipid peroxidation, resulting in decreased membrane fluidity, intracellular calcium dysregulation, depolarization, and impaired LTP. The damaging effects of HMW-Aβ1-42 were significantly greater than those of LMW-Aβ1-42. Therapeutic reduction of HMW-Aβ1-42 may prevent AD progression by ameliorating direct neuronal membrane damage.-Yasumoto, T., Takamura, Y., Tsuji, M., Watanabe-Nakayama, T., Imamura, K., Inoue, H., Nakamura, S., Inoue, T., Kimura, A., Yano, S., Nishijo, H., Kiuchi, Y., Teplow, D. B., Ono, K. High molecular weight amyloid β1-42 oligomers induce neurotoxicity via plasma membrane damage.

    DOI: 10.1096/fj.201900604R

    PubMed

    researchmap

  • Construction of an All-in-one Double-conditional shRNA Expression Vector Reviewed

    Yoshiko KUDO, Hideto OYAMADA, Tomoyuki MATSUOKA, Ayami INAGAKI, Hiromichi TSUCHIYA, Yoko AO, Atsushi Michael KIMURA, Mayumi TSUJI, Katsuji OGUCHI, Yuji KIUCHI

    The Showa University Journal of Medical Sciences   31 ( 1 )   41 - 50   2019.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • 進行性の認知症、錐体路・錐体外路症状、運動失調を認め、診断に苦慮した79歳女性例 Reviewed

    鍋島 陽子, 木村 篤史, 所澤 任修, 二村 明徳, 黒田 岳志, 村上 秀友, 小野 賢二郎

    臨床神経学   59 ( 5 )   298 - 298   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

    researchmap

  • DATスキャンの視覚評価がParkinson病の初回ドパミン補充療法に伴う遂行機能の変化を予測する Reviewed

    村上 秀友, 木村 篤史, 安本 太郎, 三木 綾子, 山本 謙, 井藤 尚仁, 門馬 佑太郎, 大湾 喜行, 黒田 岳志, 齋藤 悠, 矢野 怜, 小野 賢二郎

    神経治療学   35 ( 6 )   S253 - S253   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本神経治療学会  

    researchmap

  • Cerebrospinal fluid 5-HIAA concentrations correlate with cardiac uptake of <sup>123</sup>I-MIBG during myocardial scintigraphy in drug naïve Parkinson's disease. Reviewed International journal

    Murakami H, Yamamoto K, Yasumoto T, Kimura A, Sakae Y, Nomoto S, Kubota S, Watanabe D, Watanabe K, Saito Y, Yano S, Ono K

    Journal of neural transmission (Vienna, Austria : 1996)   125 ( 10 )   1511 - 1514   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We examined the correlations between cerebrospinal fluid (CSF) concentrations of homovanillic acid (HVA) and 5-hydroxyindole acetic acid (5-HIAA) and imaging assessment scores, using 123I-Ioflupane SPECT and 123I-MIBG myocardial scintigraphy in 23 drug naïve PD patients. The CSF 5-HIAA concentration correlated with the H/M ratio of the delayed image (r = 0.458, p < 0.05) and the washout rate (r = - 0.642, p < 0.01) of 123I-MIBG myocardial scintigraphy. These correlations suggest some unclarified pathophysiological links between the central serotonergic and cardiac sympathetic systems.

    DOI: 10.1007/s00702-018-1917-x

    PubMed

    researchmap

  • 病理学的に封入体筋炎が疑われステロイド反応性が良好であった81歳男性例

    木村 篤史, 小口 達敬, 兼元 みずき, 矢野 怜, 金野 竜太, 清水 潤, 小野 賢二郎

    臨床神経学   58 ( 8 )   526 - 526   2018.8

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

    researchmap

  • Usefulness Differs Between the Visual Assessment and Specific Binding Ratio of <sup>123</sup>I-Ioflupane SPECT in Assessing Clinical Symptoms of Drug-Naïve Parkinson's Disease Patients. Reviewed International journal

    Murakami H, Kimura A, Yasumoto T, Miki A, Yamamoto K, Ito N, Momma Y, Owan Y, Yano S, Ono K

    Frontiers in aging neuroscience   10   412 - 412   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: In clinical practice, assessment of the striatal accumulation in 123I-ioflupane single photon emission computed tomography (SPECT) is commonly performed calculating the specific binding ratio (SBR) for the whole striatum. On the other hand, visual assessment of striatal accumulation in the SPECT was recently established. However, correlations of visual assessment with motor and cognitive functions in Parkinson's disease (PD) have rarely been examined. Differences in the usefulness of these assessments at clinics are uncertain. Objective: We performed this study to compare correlations of cognitive and motor functions in drug-naive PD between the SBR and visual assessment using 123I-ioflupane SPECT. Methods: Cognitive and motor assessments and 123I-ioflupane SPECT were performed in 47 drug-naïve PD patients with Mini-mental State Examination scores of ≥25. Cognitive function was assessed using the total score and 6 subscores of the Montreal Cognitive Assessment (MoCA) and 10 separate subtests of the Neurobehavioral Cognitive Status Examination (COGNISTAT). Motor function was assessed using the Hoehn and Yahr scale and Unified Parkinson's Disease Rating Scale. Accumulation of 123I-ioflupane was determined by visual assessment based on five grades: 1, burst striatum; 2, egg-shaped; 3, mixed type; 4, eagle wing; 5, normal striatum; and by calculating SBR averaged for the bilateral striatum using the DaTView computer software commonly used in clinical practice. Each SPECT assessment was compared with each subscore for cognitive and motor assessments. Results: Spearman correlation analysis showed SBR was significantly correlated with the MoCA subscores of visuospatial function and attention, and with COGNISTAT subtests of attention. Visual assessment showed significant negative correlation with the Hoehn and Yahr scale. Mean score of postural instability in patients with visual grade of 1 was significantly higher than those in patients with visual grades of 2 and 3. Conclusion: Clinical symptoms reflected by 123I-ioflupane SPECT differ between the SBR and visual assessment. SBR reflects some cognitive functions, whereas a visual assessment grade of 1, which signifies decreased uptake of 123I-Ioflupane in the caudate nucleus, reflects postural instability. Thus, the caudate nucleus may play an important role in posture maintenance. Our results suggest that performing both assessments is of value.

    DOI: 10.3389/fnagi.2018.00412

    PubMed

    researchmap

▶ display all

Books

  • BRAIN and NERVE Vol.76 No.9

    Atsushi Michael Kimura, Hitoshi Shimada( Role: Contributor ,  Clinical Implementation of Amyloid PET : Latest Findings and Practical Approaches in the Diagnosis and Treatment of Alzheimer's Disease)

    Igaku Shoin  2024.9 

     More details

  • Precision Medicine 2024年7月号 認知症診療の最前線

    木村 篤史, 島田 斉( Role: Contributor ,  おさえておきたい認知症画像集)

    北隆館 ニュー・サイエンス社  2024.6 

     More details

MISC

  • 早期の免疫治療により良好な転帰を辿ったNew-onset refractory status epilepticusの27歳女性例

    松岡馨, 小澤準之輔, 浅野未希, 木村篤史, イズデプスキ彬子, 久保田怜美, 飯塚奈都子, 渡辺慶子, 黒田岳志, 稗田宗太郎, 小野賢二郎

    臨床神経学(Web)   62 ( 8 )   2022

  • αシヌクレイン高分子オリゴマーによる神経細胞障害機序の解明

    井藤尚仁, 井藤尚仁, 辻まゆみ, 池中健介, CESAR Aguirre, 小口達敬, 小口達敬, 木村篤史, 門馬佑太郎, 門馬佑太郎, 野原哲人, 野原哲人, 大橋英朗, 大橋英朗, 山本謙, 山本謙, 永田未希, 村上秀友, 望月秀樹, 小野賢二郎, 木内祐二, 木内祐二

    Dementia Japan   36 ( 4 )   2022

  • Vitamin B12 may prevent Aβ oligomer‐induced neurotoxicity in Alzheimer's disease

    Atsushi Michael Kimura, Mayumi Tsuji, Taro Yasumoto, Tatsunori Oguchi, Yukiko Mori, Satoshi Yano, Ryuta Kinnno, Shiro Nakamura, Tomio Inoue, David B. Teplow, Yuji Kiuchi, Kenjiro Ono

    Alzheimer's & Dementia   16 ( S9 )   2020.12

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper, summary (international conference)   Publisher:Wiley  

    DOI: 10.1002/alz.045043

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/alz.045043

  • 高分子Aβオリゴマーは細胞膜完全性を崩壊し細胞毒性を発揮する

    安本太郎, 安本太郎, 高村雄策, 辻まゆみ, 中山隆宏, 今村恵子, 井上治久, 中村史朗, 井上富雄, 木村篤史, 木村篤史, 矢野怜, 西条寿夫, 木内祐二, テプロフ デービッド, 小野賢二郎

    Dementia Japan   34 ( 4 )   2020

  • 進行性の認知症,錐体路・錐体外路症状,運動失調を認め,診断に苦慮した79歳女性例

    鍋島陽子, 木村篤史, 所澤任修, 二村明徳, 黒田岳志, 村上秀友, 小野賢二郎

    臨床神経学(Web)   59 ( 5 )   2019

  • 高分子Aβオリゴマーは細胞膜傷害を介して神経細胞毒性を発揮する

    安本太郎, 安本太郎, 高村雄策, 辻まゆみ, 中山隆宏, 今村恵子, 井上治久, 中村史朗, 井上富雄, 木村篤史, 矢野怜, 西条寿夫, 木内祐二, テプロフ デイビッド

    Dementia Japan   33 ( 4 )   2019

  • 未投薬のParkinson病の脳脊髄液の5-HIAA濃度は心臓交感神経機能と関連する

    村上 秀友, 山本 謙, 安本 太郎, 木村 篤史, 栄 良樹, 野元 祥平, 久保田 怜美, 渡辺 大士, 渡辺 慶子, 齋藤 悠, 小野 賢二郎

    パーキンソン病・運動障害疾患コングレスプログラム・抄録集   12回   92 - 92   2018.7

     More details

    Language:Japanese   Publisher:Movement Disorder Society of Japan (MDSJ)  

    researchmap

  • DATスキャンの視覚評価がParkinson病の初回ドパミン補充療法に伴う遂行機能の変化を予測する

    村上秀友, 木村篤史, 安本太郎, 三木綾子, 山本謙, 井藤尚仁, 門馬佑太郎, 大湾喜行, 黒田岳志, 齋藤悠, 矢野怜, 小野賢二郎

    神経治療学(Web)   35 ( 6 )   2018

▶ display all

Presentations

  • Vitamin B12 may inhibit the neurotoxicity of Amyloid beta oligomers and protect memory function

    Atsushi Kimura, Taro Yasumoto, Yukiko Mori, Yutaro Momma, Tetsuhito Nohara, Akinori Futamura, Takeshi Kuroda, Hideyo Kasai, Ryuta Kinno, Sotaro Hieda, David Teplow, Mayumi Tsuji, Yuji Kiuchi, Hitoshi Shimada, Hidetomo Murakami, Kenjiro Ono

    2023.5 

     More details

    Event date: 2023.5 - 2023.6

    Language:English  

    researchmap

  • Effects of Vitamin B12 on cognitive function in elderly patients

    Atsushi Michael Kimura, Ryuta Kinnno, Mayumi Tsuji, Kenjiro Ono

    Alzheimer’s Association International Conference 2021 

     More details

    Event date: 2021.7

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Myricetin prevents Aβ oligomers-induced neurotoxicity via cell membrane damage

    Atsushi Michael Kimura, T. Yasumoto, Y. Mori, T. Oguchi, M. Umino, A. Umino, S. Nakamura, T. Inoue, M. Yamada, D.Teplow, Y. Kiuchi, M. Tsuji, K. Ono

    15th International Conference on Alzheimer‘s & Parkinson‘s Diseases  2021.3 

     More details

    Event date: 2021.3

    Language:English   Presentation type:Poster presentation  

    researchmap

  • ビタミンB12はアミロイドβオリゴマーによる 神経毒性を抗酸化作⽤により抑制する

    2020.11 

     More details

    Event date: 2020.11

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • Vitamin B12 may prevent Aβ oligomer-induced neurotoxicity in Alzheimer's Disease

    Atsushi Michael Kimura, Mayumi Tsuji, Taro Yasumoto, Tatsunori Oguchi, Yukiko Mori, Satoshi Yano, Ryuta Kinnno, Shiro Nakamura, Tomio Inoue, David B Teplow, Yuji Kiuchi, Kenjiro Ono

    Alzheimer’s Association International Conference 2020  2020.7 

     More details

    Event date: 2020.7

    Language:English   Presentation type:Poster presentation  

    researchmap

  • From clinic to cell: Cobalamin's multi-faceted approach to understanding defense against amyloid beta oligomer neurotoxicity

    AD/PD 2024 - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders.  2024.3 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • 進行性核上性麻痺とアルツハイマー型認知症の合併が疑われた1例

    鍋島 陽子, 木村 篤史, 所澤 任修, 二村 明徳, 黒田 岳志, 村上 秀友, 小野 賢二郎

    日本内科学会関東地方会 665回 55-55 2020年12月  2020.12 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • High molecular weight amyloid β oligomer induces disruption and structural change of cell membrane

    YASUMOTO Taro, TAKAMURA Yusaku, TSUJI Mayumi, NAKAYAMA Takahiro, IMAMURA Keiko, INOUE Haruhisa, NAKAMURA Shiro, INOUE Tomio, Atsushi Michael Kimura, YANO Satoshi, NISHIJO Hisao, KIUCHI Yuji, David B TEPLOW, ONO Kenjiro

    第61回日本神経学会学術大会  2020.8 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • High molecular weight amyloid β1-42 oligomers induce neurotoxicity via plasma membrane damage

    YASUMOTO Taro, TAKAMURA Yusaku, TSUJI Mayumi, NAKAYAMA Takahiro, IMAMURA Keiko, INOUE Haruhisa, NAKAMURA Shiro, INOUE Tomio, Atsushi Michael Kimura, YANO Satoshi, NISHIJO Hisao, KIUCHI Yuji, David B TEPLOW, ONO Kenjiro

    Alzheimer's Association International Conference 2020  2020.7 

     More details

    Presentation type:Poster presentation  

    researchmap

  • Myricetin prevents Aβ oligomers-induced neurotoxicity via cell membrane damage

    Atsushi Michael Kimura, T. Yasumoto, Y. Mori, T. Oguchi, M. Umino, A. Umino, S. Nakamura, T. Inoue, M.Yamada, D. B. Teplow, Y. Kiuchi, M. Tsuji, K. Ono

    15th International Conference on Alzheimer’s and Parkinson’s Diseases  2020.4 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • 高分子Aβオリゴマーは細胞膜傷害を介して神経細胞毒性を発揮する

    安本 太郎, 高村 雄策, 辻 まゆみ, 中山 隆宏, 今村 恵子, 井上 治久, 中村 史朗, 井上 富雄, 木村 篤史, 矢野 怜, 西条 寿夫, 木内 祐二, テプロフ デイビッド, 小野 賢二郎

    第38回日本認知症学会学術集会  2019.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Construction and integration of the All-in-One type single double-conditional shRNA expression vectors for spatio-temporal gene and/or cell targeting

    Hideto Oyamada

    he 42nd Annual Meeting of the Japan Neuroscience Society (2019)  2019.7 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Effects of Vitamin B12 on memory function in elderly patients

    Atsushi Michael Kimura

    60th Annual Meeting of the Japanese Society of Neurology  2019.5 

     More details

    Language:English  

    researchmap

  • Effects of vitamin B12 on memory function and complexity of the cortical structure

    Atsushi Michael Kimura

    59th Annual Meeting of the Japanese Society of Neurology  2018.5 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • 病理学的に封入体筋炎が疑われステロイド反応性が良好であった81歳男性例

    木村 篤史, 小口達敬, 兼元みずき, 矢野怜, 金野竜太, 清水潤, 小野賢二郎

    第224回日本神経学会関東・甲信越地方会  2018.3 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 尿閉に起因する肺塞栓をきたしたElsberg症候群の1 例

    木村篤史, 関大成, 杉山雄亮, 勝又淳子, 前川理沙, 日出山拓人, 椎尾康

    日本内科学会関東地方会  2016.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 特異な機序により絞扼性イレウスを生じたメッケル憩室の一例

    木村 篤史, 寺下 勇祐, 織畑 光一, 長谷川 智彦, 竹島 雅子, 下里 あゆ子, 永吉 実紀子, 佐藤 兼俊, 村田 祐二郎, 緒方 晴樹, 奥田 純一, 津久井 元, 寺島 裕夫

    第841回外科集談会 優秀演題  2016.6 

     More details

    Language:Japanese  

    researchmap

  • 急速進行性腎炎症候群を呈する​顕微鏡的多発血管炎(MPA)に対し、​血漿交換療法を施行し維持透析を離脱した一例

    木村篤史, 松村実美子, 宇仁理恵, 東原崇明, 高野秀樹, 清水章

    日本内科学会関東地方会  2016.3 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

▶ display all

Awards

  • The 1st place in the Ideathon's outstanding presentation award, Society of Young Scientists for Dementia Research, Japan Society for Dementia Research

    2023  

     More details

  • Showa University Graduate School of Medicine, Valedictorian

    2021  

     More details

  • Best Resident of Tokyo Teishin Hospital

    2017  

     More details

  • 841st Surgical Colloquium Resident Encouragement Award

    2016  

     More details

  • Joint Seminar for Four Hospitals for Clinical Training Resident Award and Outstanding Discussion Hospital Award

    2016  

     More details

  • Niigata University Student Academic Excellence Award

    2010  

     More details

▶ display all

Research Projects

  • チアミンによるアルツハイマー病の予防・進行抑制機序の多面的解明:基礎から臨床へ

    Grant number:23K16804

    2023.4 - 2026.3

    System name:科学研究費助成事業

    Research category:若手研究

    Awarding organization:日本学術振興会

    木村 篤史

      More details

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    researchmap

  • Investigation of the mechanism of vitamin B12 to prevent Alzheimer's disease: from basic to clinical research

    Grant number:20K19685

    2020.4 - 2024.3

    System name:Grants-in-Aid for Scientific Research

    Research category:Grant-in-Aid for Early-Career Scientists

    Awarding organization:Japan Society for the Promotion of Science

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    researchmap

 

Teaching Experience (researchmap)